BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanios BY, Itani HS, Zimmerman DL. Clopidogrel Use in End-Stage Kidney Disease. Semin Dial 2015;28:276-81. [DOI: 10.1111/sdi.12338] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Burlacu A, Genovesi S, Ortiz A, Combe C, Basile C, Schneditz D, van der Sande F, Popa GT, Morosanu C, Covic A. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant 2019;34:923-33. [PMID: 30879070 DOI: 10.1093/ndt/gfz040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
2 Leiva O, Bekendam RH, Garcia BD, Thompson C, Cantor A, Chitalia V, Ravid K. Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs. TH Open 2019;3:e165-70. [PMID: 31259299 DOI: 10.1055/s-0039-1692204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Singh N, Ding L, Magee GA, Shavelle DM, Kashyap VS, Garg PK. Discharge Prescription Patterns for Antiplatelet Therapy Following Lower Extremity Peripheral Vascular Intervention. Circ Cardiovasc Interv 2020;13:e008791. [PMID: 32791948 DOI: 10.1161/CIRCINTERVENTIONS.119.008791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Vazzana N, Santilli F, Lattanzio S, Liani M, Giacci L, Del Rosso G, Salvati F, Boccatonda A, Ferroni P, Davì G. Determinants of thromboxane biosynthesis in patients with moderate to severe chronic kidney disease. Eur J Intern Med 2016;33:74-80. [PMID: 27389698 DOI: 10.1016/j.ejim.2016.06.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
5 Leonard CE, Zhou M, Brensinger CM, Bilker WB, Soprano SE, Pham Nguyen TP, Nam YH, Cohen JB, Hennessy S. Clopidogrel Drug Interactions and Serious Bleeding: Generating Real-World Evidence via Automated High-Throughput Pharmacoepidemiologic Screening. Clin Pharmacol Ther 2019;106:1067-75. [PMID: 31106397 DOI: 10.1002/cpt.1507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Lauder L, Ewen S, Emrich IE, Böhm M, Mahfoud F. [Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure]. Herz 2019;44:611-29. [PMID: 31468075 DOI: 10.1007/s00059-019-04846-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Soh RY, Sia C, Lau R, Ho P, Timothy NY, Ho JS, Kaur H, Sim H, Yeo T, Tan H, Chan MY, Loh JP. The impact of chronic kidney disease on long-term outcomes following semi-urgent and elective percutaneous coronary intervention. Coronary Artery Disease 2021;32:517-25. [DOI: 10.1097/mca.0000000000000980] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Lau WL. Controversies: Stroke Prevention in Chronic Kidney Disease. J Stroke Cerebrovasc Dis 2021;30:105679. [PMID: 33640261 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105679] [Reference Citation Analysis]
9 De Santis F, Boari A, Dondi F, Crisi PE. Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease. Animals 2022;12:262. [DOI: 10.3390/ani12030262] [Reference Citation Analysis]
10 Voroneanu L, Ortiz A, Nistor I, Covic A. Atrial fibrillation in chronic kidney disease. European Journal of Internal Medicine 2016;33:3-13. [DOI: 10.1016/j.ejim.2016.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Kelly DM, Rothwell PM. Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. Kidney Int 2020;97:266-78. [PMID: 31866114 DOI: 10.1016/j.kint.2019.09.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
12 Wagner LA, Fink JC. Ensuring Patient Safety During the Transition to ESRD. Semin Nephrol 2017;37:194-208. [PMID: 28410653 DOI: 10.1016/j.semnephrol.2016.12.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]